Waters Corporation reports recurring developments across life sciences and diagnostics, including analytical instruments, informatics, service, and high-volume testing workflows. News for WAT commonly covers operating results and guidance, the Analytical Sciences Division, and the Biosciences and Diagnostic Solutions businesses added through the completed BD transaction.
Company updates also include product launches for liquid chromatography, UPLC and UHPLC workflows, MALS detection, rheometry, LC columns, and TA Instruments technologies. Diagnostic news includes FDA-related developments for the Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, along with commercial, conference, and shareholder-related updates.
Waters Corporation (NYSE:WAT) has appointed John M. Ballbach to its Board of Directors, effective October 5, 2021. This appointment follows the retirement of Dr. Michael J. Berendt, who served on the board for over two decades. Ballbach brings extensive experience in the life sciences tools sector, with a robust background in M&A and operational excellence. His appointment comes at a pivotal time for Waters as the company aims to enhance its growth and value creation strategies.
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, a new LC-MS system aimed at enhancing multi-attribute monitoring of biotherapeutics. This system significantly improves analyte recovery and assay reproducibility, addressing challenges posed by analyte-to-metal interactions. Expected to facilitate quicker access to mass spectrometry data, the system aims to lower costs and expedite the delivery of medicines to patients. Customer shipments are set to commence at the month’s end.
Waters Corporation (NYSE:WAT) has launched the BioAccord System with ACQUITY Premier, an advanced LC-MS system designed for improved monitoring of biotherapeutics. This system significantly enhances analyte recovery and assay reproducibility, allowing faster access to critical data about biologics. Key features include MaxPeak HPS technology, which eliminates analyte-to-metal interactions, resulting in up to 300% increase in sensitivity for glycan profiling. Shipments are expected to begin soon, which may help accelerate the delivery of essential medicines to patients.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will present at the Bank of America Global Healthcare Conference on September 16, 2021, at 3:55 PM BST (10:55 AM Eastern Time). Investors can access the live webcast on Waters' investor relations website. Waters, a leader in specialty measurement, has over 7,400 employees and operates in 35 countries, with products available in more than 100 countries.
Waters Corporation (NYSE:WAT) announced that its CEO, Udit Batra, will engage in a virtual fireside chat at Morgan Stanley’s 19th Annual Global Healthcare event on September 14th, 2021, at 8:45 AM EST. Investors can access the live webcast through Waters’ investor relations website. Waters has been a leader in chromatography and mass spectrometry for over 60 years, with more than 7,400 employees across 35 countries.
Waters Corporation reported a strong second quarter 2021 with sales reaching $682 million, a 31% increase from $520 million a year prior, driven by a 4% boost from foreign currency translation. GAAP diluted EPS rose to $2.69 from $1.98 in Q2 2020. For the first half of 2021, sales grew to $1,290 million, with 31% growth compared to the same period last year. The company anticipates full-year sales growth between 13% to 15% and expects non-GAAP EPS of $10.50 to $10.70.
Waters Corporation (NYSE:WAT) will host a live webcast for its Q2 2021 financial results on August 3, 2021, at 8:00 a.m. ET. Investors can access the call through Waters' official website. The replay will be available until August 10, 2021. Waters is a leader in specialty measurement, focusing on chromatography, mass spectrometry, and thermal analysis for life, materials, and food sciences. With over 7,400 employees and operations in 35 countries, Waters has a significant global presence.
Waters Corporation (NYSE:WAT) has launched the TRIOS AutoPilot software, enhancing its thermal analyzer product line under the TA Instruments Division. This software allows laboratory staff to develop standard operating procedures (SOPs) up to 25% faster and eliminates transcription errors, improving productivity and consistency in thermal analysis. It utilizes Google’s Blockly interface, making it user-friendly for script creation without advanced programming skills. The TRIOS AutoPilot includes built-in compliance features, ensuring regulatory adherence, and is available globally.
Waters Corporation (NYSE:WAT) has expanded its collaboration with Singapore's Bioprocessing Technology Institute (BTI) to enhance analytics in glycomics and metabolomics. The partnership aims to improve the rapid identification of complex biomolecules that are crucial for biologics manufacturing. Utilizing advanced instruments like the SYNAPT™ mass spectrometry system, the project addresses the challenges of characterizing biopharmaceuticals through data analytics and machine learning. This collaboration builds on a successful relationship since 2014, targeting cost reduction and efficiency in biomanufacturing processes.
Waters Corporation (NYSE: WAT) has appointed Wei Jiang to its Board of Directors, effective July 14, 2021. Wei currently serves as Executive Vice President at Bayer Pharmaceuticals for the China and APAC regions. His expertise in driving results in fast-growing markets, particularly in China, is viewed as a significant asset for Waters. Dr. Udit Batra, CEO, notes that Wei's experience aligns with the company's growth strategy in the pharmaceutical sector. Wei expressed enthusiasm about contributing to Waters' ongoing transformation, highlighting growth potential in China's pharma market.